Showing results (201-210 of 239) with videos related to
Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2016
Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine GliomasJennifer E Kim, Mira A Patel, Antonella Mangraviti, et al.The American Journal of Pathology|September 6, 2011
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypesChristopher M Heaphy, Andrea P Subhawong, Seung-Mo Hong, et al.Oncotarget|October 29, 2013
Alterations of immune response of Non-Small Cell Lung Cancer with AzacytidineJohn Wrangle, Wei Wang, Alexander Koch, et al.Journal for Immunotherapy of Cancer|April 3, 2020
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance TaskforceHarriet M Kluger, Hussein A Tawbi, Maria L Ascierto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2024
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous CancersKara M Schenk, Julie Stein Deutsch, Sunandana Chandra, et al.JCO Precision Oncology|November 29, 2022
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker SummitDaniel F Hayes, Roy S Herbst, Jonathan L Myles, et al.The New England Journal of Medicine|April 11, 2022
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung CancerPatrick M Forde, Jonathan Spicer, Shun Lu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2020
Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public WorkshopKristen L Mueller, Marc R Theoret, Steven J Lemery, et al.Future Oncology (London, England)|February 23, 2023
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancerPatrick M Forde, Jonathan Spicer, Shun Lu, et al.The Lancet. Oncology|October 24, 2023
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 studyNeil D Gross, David M Miller, Nikhil I Khushalani, et al.Pageof 24